196 related articles for article (PubMed ID: 17269896)
1. Transporter-mediated drug interactions: clinical implications and in vitro assessment.
Lin JH
Expert Opin Drug Metab Toxicol; 2007 Feb; 3(1):81-92. PubMed ID: 17269896
[TBL] [Abstract][Full Text] [Related]
2. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
Varma MV; El-Kattan AF
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
4. Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions.
Lu C; Liao M; Cohen L; Xia CQ
Curr Drug Discov Technol; 2010 Sep; 7(3):199-222. PubMed ID: 20843292
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
6. [Mechanisms of pharmacokinetic drug-drug interactions].
Levêque D; Lemachatti J; Nivoix Y; Coliat P; Santucci R; Ubeaud-Séquier G; Beretz L; Vinzio S
Rev Med Interne; 2010 Feb; 31(2):170-9. PubMed ID: 19740579
[TBL] [Abstract][Full Text] [Related]
7. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
8. Interplay of Drug-Metabolizing Enzymes and Transporters in Drug Absorption and Disposition.
Shi S; Li Y
Curr Drug Metab; 2014; 15(10):915-41. PubMed ID: 25828591
[TBL] [Abstract][Full Text] [Related]
9. Application of in vitro CYP and transporter assays to predict clinical drug-drug interactions.
Volpe DA; Balimane PV
Bioanalysis; 2018 May; 10(9):619-623. PubMed ID: 29768028
[No Abstract] [Full Text] [Related]
10. Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.
Momper JD; Tsunoda SM; Ma JD
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S82-98. PubMed ID: 27385182
[TBL] [Abstract][Full Text] [Related]
11. Sandwich-Cultured Hepatocytes for Mechanistic Understanding of Hepatic Disposition of Parent Drugs and Metabolites by Transporter-Enzyme Interplay.
Matsunaga N; Fukuchi Y; Imawaka H; Tamai I
Drug Metab Dispos; 2018 May; 46(5):680-691. PubMed ID: 29352067
[TBL] [Abstract][Full Text] [Related]
12. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.
Lam YW; Alfaro CL; Ereshefsky L; Miller M
J Clin Pharmacol; 2003 Nov; 43(11):1274-82. PubMed ID: 14551182
[TBL] [Abstract][Full Text] [Related]
14. Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions.
Langer O
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S143-56. PubMed ID: 27385172
[TBL] [Abstract][Full Text] [Related]
15. Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates.
Mandlekar SV; Rose AV; Cornelius G; Sleczka B; Caporuscio C; Wang J; Marathe PH
Xenobiotica; 2007 Sep; 37(9):923-42. PubMed ID: 17896322
[TBL] [Abstract][Full Text] [Related]
16. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.
Tham LS; Lee HS; Wang L; Yong WP; Fan L; Ong AB; Sukri N; Soo R; Lee SC; Goh BC
Ther Drug Monit; 2006 Apr; 28(2):255-61. PubMed ID: 16628140
[TBL] [Abstract][Full Text] [Related]
17. Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues.
Wulkersdorfer B; Wanek T; Bauer M; Zeitlinger M; Müller M; Langer O
Clin Pharmacol Ther; 2014 Aug; 96(2):206-13. PubMed ID: 24682030
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
[TBL] [Abstract][Full Text] [Related]
19. A pharmaceutical industry perspective on transporter and CYP-mediated drug-drug interactions: kidney transporter biomarkers.
Shen H
Bioanalysis; 2018 May; 10(9):625-631. PubMed ID: 29768022
[No Abstract] [Full Text] [Related]
20. Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.
Feng B; Varma MV
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S110-21. PubMed ID: 27385169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
